Cyclosporine for SJS/TEN: A case series and review of the literature

Cutis

Volumn 87, Issue 1, 2011, Pages 24-29

  Reese, Drew ^a   Henning, J Scott ^a   Rockers, Kyle ^a   Ladd, Denise ^a   Gilson, Robert ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CYCLOSPORIN; DERMATOLOGICAL AGENT; LAMOTRIGINE; PARACETAMOL; SULFAMETHIZOLE; TRIAZINE DERIVATIVE; TRIMETHOPRIM; TRIMETHOPRIM SULFAMETHIZOLE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HUMAN; MALE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; STEVENS-JOHNSON SYNDROME; SULFAMETHIZOLE; TRIAZINES; TRIMETHOPRIM;

EID: 79951934513     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97:272-283, 320.
2. Paquet P, Piérard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome)[published online ahead of print February 15, 2005]. Int Arch Allergy Immunol. 2005;136:205-216.
3. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol. 1995;131:669-672.
4. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204:503-512.
5. Halebian PH, Shires GT. Burn unit treatment of acute, severe exfoliating disorders. Annu Rev Med. 1989;40:137-147.
6. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56:181-200.
7. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33-36.
8. Paquet P, Jacob E, Damas P, et al. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res. 2005;297:266-273.
9. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155:722-728.
10. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004;123:850-855.
11. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225-230.
12. Paquet P, Piérard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review). Int J Mol Med. 2007;19:3-10.
13. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.
14. Paquet P, Piérard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology. 1999;198:198-202.
15. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuro-blastoma cells. Cancer Res. 1997;57:3823-3829.